Health

Add as a preferred source on Google

Sobi Says EU Expands Tryngolza Approval for Severely High Triglycerides

Sobi said the new EU severe hypertriglyceridemia indication begins at 880 mg/dL. The comparable U.S. indication starts at 500 mg/dL.

Updated 2 min read
Pedestrians pass the European Commission's Berlaymont building in Brussels, Belgium. / EconoTimes.ai
Pedestrians pass the European Commission's Berlaymont building in Brussels, Belgium. / EconoTimes.ai

Swedish Orphan Biovitrum AB (publ), or Sobi, said Tuesday that the European Commission widened approval of Tryngolza (olezarsen) for adults with severely high triglycerides, expanding the drug’s eligible patient group in Europe.

Under the indication Sobi announced, adults with fasting triglycerides of at least 880 mg/dL (10 mmol/L) may receive the drug alongside diet and other lipid-lowering medicines. The U.S. Food and Drug Administration (FDA) approved Tryngolza for severe hypertriglyceridemia at a lower threshold of 500 mg/dL.

Evidence on pancreatitis came from the CORE and CORE2 trials, whose primary analysis included 1,061 treated adults. Over roughly a year, researchers recorded seven acute pancreatitis episodes among 705 olezarsen recipients and 22 among 356 placebo recipients. Their pooled analysis found an 85% lower event rate with olezarsen.

Of those in the primary analysis, 455 entered the trials with triglycerides at or above the new EU cutoff. Sobi’s cited 83% lower pancreatitis event rate applies to a narrower group of 141 participants who also had a history of pancreatitis.

In CORE, the 80-mg group’s triglyceride reduction at six months exceeded the placebo group’s by 72.2 percentage points. That was the largest of four overall primary comparisons across CORE and CORE2. Those comparisons covered trial populations admitted at 500 mg/dL or higher, including patients below the new EU threshold.

Researchers found more elevated liver enzymes and low platelet counts with the 80-mg dose. A separate MRI substudy of 252 participants found that liver fat increased with dose.

Tryngolza was already authorized in the EU for familial chylomicronemia syndrome, a rare inherited condition. The European Medicines Agency (EMA) said its Committee for Medicinal Products for Human Use (CHMP) recommended the wider indication in October.

Ionis Pharmaceuticals, Inc. developed Tryngolza and markets it in the United States. Sobi holds the drug’s EU commercialization rights under a license from Ionis.

Related articles

View all